-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The industry generally believes that from the perspective of technology, business models and policies, the future development opportunities and challenges of medical artificial intelligence coexist, "fire and fury", but also need a sound model and rational market to verify. In this regard, Guangzhou Women's and Children's Medical Center Director Xia Huimin, Guangzhou Jindao Medical Inspection Group Co., Ltd. Chief Scientific Officer Yu Shihui and other experts suggested:
countries led the construction of databases, connecting "islands" to achieve medical data sharing. Yu Shihui believes that artificial intelligence is actually the process of recreating data, data barriers, sample barriers the most fundamental problem or enterprises, institutions to safeguard their respective interests. To solve the problem of data sharing requires government-led, enterprise-involved, jointly forming a sample library to solve the problem of data standardization.
clear legal standards for medical AI diagnosis into clinical applications. For "the main body of artificial intelligence diagnosis in law is a doctor or a medical device", the industry suggests that the current medical imaging artificial intelligence has entered a critical stage of development, its top priority is to do a good job in standard construction, improve the relevant policies. According to the U.S. experience, medical imaging products, for example, are used to detect physical conditions, and second, to assess diseases, the former belongs to the second category of devices, the latter is a higher risk level of three types of devices. At present, the U.S. Food and Drug Administration approved by the medical imaging artificial intelligence products are mostly classified as second-class equipment, in the approval of such devices have accumulated a lot of experience, can provide the corresponding approval standards.
to promote high-end talent gathering through government-enterprise cooperation. In 2017, the Ministry of Science and Technology announced the first batch of national AI open innovation platform list, Baidu, Alibaba Cloud, Tencent, Science and Technology News Fly and other four enterprises shortlisted, enterprises deeply involved in cross-disciplinary research, will be the development of national artificial intelligence gathered a large number of human resources, and further promote cooperation in production, research and development. Experts believe that China is likely to achieve world-class results in technologies such as autonomous driving and speech recognition, and is expected to integrate research talents from these fields and deeply participate in medical artificial intelligence.
to play the existing advantages of grafting algorithm to achieve "bend oversized." Xia Huimin suggested that Chinese enterprises should take advantage of the advantages of big data development, the use of existing international sharing platform for the introduction of digestion and absorption and re-innovation, such as through the Google platform to develop new algorithms, through "migration learning" one by one, can be in a short period of time, in some projects to reach or even surpass the international advanced level, and to form a large-scale comprehensive advantage. (Economic Reference)